Myocardial infarction codes, diagnosis added on or after 1st April 2003.
G30..% G30.. Acute myocardial infarction to G30z. Acute myocardial
infarction NOS
G35..% G35.. Subsequent myocardial infarction to G35X. Subsequent
myocardial infarction of unspecified site
G38..% G38.. Postoperative myocardial infarction to G38z. Postoperative
myocardial infarction, unspecified
Gyu34 [X]Acute transmural myocardial infarction of unspecified site
Ace inhibitor contraindications; persistent
- 14LM. H/O: angiotensin converting enzyme inhibitor allergy
- U60C4 [X]Angiotensin-converting-enzyme inhibitors causing adverse effects
in therapeutic use
- ZV14D [V]Personal history of angiotensin-converting-enzyme inhibitor allergy
TJC77 Adverse reaction to captopril
TJC78 Adverse reaction to enalapril
TJC79 Adverse reaction to ramipril
Ace inhibitor contraindications; expiring (in the last 15 months)
- 8I28. Angiotensin converting enzyme inhibitors contraindicated
- 8I3D. Angiotensin converting enzyme inhibitor declined
- 8I64. Angiotensin converting enzyme inhibitor not indicated
- 8I74. Angiotensin converting enzyme inhibitor not tolerated
AII antagonist contraindications: persisting
- 14LN. H/O: angiotensin II receptor antagonist allergy
- U60CB [X]Angiotensin II receptor antagonists causing adverse effects in
therapeutic use
- ZV14E [V]Personal history of angiotensin II receptor antagonist allergy
AII antagonist contraindications: expiring (in the last 15 months)
- 8I2H. Angiotensin II receptor antagonists contraindicated
- 8I3P. Angiotensin II receptor antagonist declined
- 8I6C. Angiotensin II receptor antagonist not indicated
- 8I75. Angiotensin II receptor antagonist not tolerated
Ace inhibitor prescription codes (prescribed in
the last 6 months)
- bi...%
- bA…%
- bk6..%
OR
AII antagonist prescription codes (prescribed in the last 6 months)
- bk3.. - bk5z.
- bk7.. - bk9z.
- bkB..%
bkD..%
CHD exception reporting codes (In last 15 months)
- 9h0.. Exception reporting: CHD quality indicators
- 9h01. Excepted from CHD quality indicators: Patient unsuitable
- 9h02. Excepted from CHD quality indicators: Informed dissent
CHD 11.1 Rationale
A number of trials have shown reduced mortality following myocardial
infarction with the use of ACE inhibitors. The Heart Outcome Prevention Evaluation
(HOPE) showed that ACE inhibitors are also of benefit in reducing coronary events
and progression of coronary arteriosclerosis in patients without left ventricular
systolic dysfunction. There is evidence that angiotensin II antagonists have
a similar effect.
Grade A Recommendation SIGN Guideline 96
Grade A Recommendation NICE Guideline A
Further information: www.sign.ac.uk/guidelines/fulltext/96/index.html
www.escardio.org/knowledge/guidelines/Guidelines_list.htm?hit=quick
CHD 11.2 Reporting and verification
The percentage of patients who have had a myocardial infarction
after 1 April 2003 whose records show they have been prescribed an ACE inhibitor
or A2 antagonist in the last six months.
Prepared By Jean Keenan